| 초록 |
Small interfering RNA(siRNA) has been impeded by several difficulties including poor activities, instability, nonspecific effects, and immune response. To overcome them, we hypothesized a stable and efficient systemic siRNA delivery system by prolonging the circulation time. Based on our previous studies, we adopted PEG-dex-dopa conjugates for coating and stabilizing the synthesized CaP/siRNA nanoparticles. We evaluated not only characterization, cytotoxicity, cellular uptake, and serum stability, but also pharmacokinetics and tumor inhibition. We demonstrated that PEG-dex-dopa/CaP/siRNA delivery system could enhance the stability of size, intracellular uptake, and serum stability without toxicity, thereby prolonging the circulation time as well as inhibiting tumor growth by targeting VEGF gene through the EPReffect in vivo. PEG-dex-dopa/CaP/siRNA biocompatible hybrid holds promise as a platform for long-circulating systemic siRNA delivery for cancer therapy. |
